Data alert

HOPE: Effect of long-term therapy with ACE inhibition in high-risk women

Cardiovascular (CV) disease is currently the leading cause of death and the main hospital diagnosis in postmenopausal women. In 1999, twice as many women died from heart disease as from cancer, and >3 million women were discharged from the hospital with a diagnosis of CV disease.1 CV mortality and morbidity in women are expected to rise in the coming decades because of increasing life expectancy and age-related increases in hypertension as well as a growing epidemic of obesity and diabetes.2 These facts highlight the importance of effective preventive strategies in women to reduce their CV risk.

References are listed at the end of the Data Alert.


Download DA11.ppt (5 slides - 0.7MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


Related at vwbg.org

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

Curriculum Update #3

Clinical Trials Update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

This Curriculum Update highlights important recent trials of tissue ACE inhibition in patients with cardiovascular disease and preserved left ventricular function.

Vascular Biology in Clinical Practice © Vol. 1, No. 4

Clinical trials update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

Advances in vascular biology bring physicians the opportunity to apply new concepts in the treatment of patients with cardiovascular disease.
More related